Estimaciones de analistas de Wall Street para Kezar Life Sciences, Inc. (KZR): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 2 |
| Mantener | 5 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 7 |
| Calificación media (1-5) | 0.29 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-08-12 | $-1.05 | ||
| 2026-05-11 | $-0.78 | $-0.98 | +20.4% |
| 2026-03-27 | $-1.99 | $-1.31 | -52.0% |
| 2025-11-12 | $-1.53 | $-1.81 | +15.5% |
| 2025-08-13 | $-1.87 | $-2.15 | +13.0% |
| 2025-05-13 | $-2.27 | $-2.56 | +11.3% |
| 2025-03-25 | $-2.77 | $-2.71 | -2.2% |
| 2024-11-12 | $-2.78 | $-3.03 | +8.3% |
Ratios de valoración
| Precio / Valor contable | 0.82 |
| EV / EBITDA | 0.46 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $7.0M | 0 | 0 |
| Coste de Ventas | $154000 | $175000 | $690000 | $1.3M | $1.5M | $1.5M | 0 | 0 | 0 | $897000 |
| Beneficio Bruto | -$154000 | -$175000 | -$690000 | -$1.3M | -$1.5M | -$1.5M | 0 | $7.0M | 0 | -$897000 |
| I+D | $7.4M | $6.5M | $18.1M | $28.0M | $31.0M | $38.9M | $51.0M | $85.7M | $65.7M | $33.8M |
| Generales y Administrativos | $1.6M | $2.3M | $6.6M | $8.7M | $10.4M | $15.7M | $20.2M | $26.5M | $23.4M | $18.5M |
| Gastos Operativos | $9.0M | $8.7M | $24.7M | $36.7M | $41.5M | $53.1M | $71.2M | $118.4M | $90.6M | $51.4M |
| Beneficio Operativo | -$9.0M | -$8.7M | -$24.7M | -$38.0M | -$43.0M | -$54.7M | -$71.2M | -$111.4M | -$90.6M | -$52.3M |
| EBITDA | -$8.8M | -$8.3M | -$22.5M | -$34.4M | -$40.3M | -$53.0M | -$66.0M | -$99.3M | -$81.1M | -$51.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | $159000 | $1.2M | $1.6M | $1.6M | 0 |
| Beneficio Antes de Impuestos | -$9.0M | -$8.5M | -$23.2M | -$35.7M | -$41.8M | -$54.6M | -$68.2M | -$101.9M | -$83.7M | -$56.0M |
| Impuestos | 0 | 0 | 0 | -$635000 | -$58000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$9.0M | -$8.5M | -$23.2M | -$35.1M | -$41.7M | -$54.6M | -$68.2M | -$101.9M | -$83.7M | -$56.0M |
| BPA | $-0.69 | $-0.65 | $-1.22 | $-1.65 | $-0.95 | $-1.04 | $-1.01 | $-1.40 | $-1.15 | $-7.66 |
| BPA Diluido | $-0.69 | $-0.65 | $-1.22 | $-1.65 | $-0.95 | $-1.04 | $-1.01 | $-1.40 | $-1.15 | $-7.66 |
| Acciones en Circulación (Diluidas) | $13.0M | $13.0M | $19.0M | $19.1M | $44.0M | $52.8M | $67.4M | $72.6M | $72.9M | $7.3M |
Precio
| Precio | $7.29 |
| Capitalización | $54M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: CCCC · CRNX · ERAS · EWTX · REPL · SRRK · STRO
Explorar sector: Healthcare · Biotechnology
Más secciones de KZR: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones